ReviewFrontiers in cell and developmental biology2021
Natural Products for the Management of Castration-Resistant Prostate Cancer: Special Focus on Nanoparticles Based Studies.
Review in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- Improved Chemosensitivity in Metastatic Castration-Resistant Prostate Cancer: The Synergistic Effects of S-Adenosylmethionine and Cabazitaxel.Cancer medicine · 2026Article
- Natural Products Repository of Costa Rica (NAPRORE-CR): An Open-Access Database.Journal of chemical information and modeling · 2025Article
- Facile synthesis of elastin nanogels encapsulated decursin for castrated resistance prostate cancer therapy.Scientific reports · 2024Article
- Natural products in the management of neurodegenerative diseases.Nutrition & metabolism · 2024Review
- Application of Quercetin and its Novel Formulations in the Treatment of Malignancies of Central Nervous System: An Updated Review of Current Evidence based on Molecular Mechanisms.Current medicinal chemistry · 2024Review
- Unlocking the Immunomodulatory Potential of Rosmarinic Acid Isolated fromCurrent medicinal chemistry · 2024Article
- Nanocarriers in Tuberculosis Treatment: Challenges and Delivery Strategies.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Improving the Antitumor Effect of Chemotherapy with Ocoxin as a Novel Adjuvant Agent to Treat Prostate Cancer.Nutrients · 2023Article
- An Insight into Advances in Developing Nanotechnology Based Therapeutics, Drug Delivery, Diagnostics and Vaccines: Multidimensional Applications in Tuberculosis Disease Management.Pharmaceuticals (Basel, Switzerland) · 2023Review
- The Role of ERα and ERβ in Castration-Resistant Prostate Cancer and Current Therapeutic Approaches.Biomedicines · 2023Review
- Phytochemicals: Alternative for Infertility Treatment and Associated Conditions.Oxidative medicine and cellular longevity · 2023Review
- Review
- Application of Nanomicelles in Enhancing Bioavailability and Biological Efficacy of Bioactive Nutrients.Polymers · 2022Review
- Insights on prospects of nano-siRNA based approaches in treatment of Cancer.Frontiers in pharmacology · 2022Review
- Chemopreventive Potential of Dietary Nanonutraceuticals for Prostate Cancer: An Extensive Review.Frontiers in oncology · 2022Review
- The Role of m6A RNA Methylation in Cancer: Implication for Nature Products Anti-Cancer Research.Frontiers in pharmacology · 2022Review
- Green Metallic Nanoparticles: Biosynthesis to Applications.Frontiers in bioengineering and biotechnology · 2022Review
- Editorial: Exploration of Natural Product Leads for Multitarget-Based Treatment of Cancer-Computational to Experimental Journey.Frontiers in pharmacology · 2022Article
- Natural Kinase Inhibitors for the Treatment and Management of Endometrial/Uterine Cancer: Preclinical to Clinical Studies.Frontiers in pharmacology · 2022Review
- The role of nanomaterials in enhancing natural product translational potential and modulating endoplasmic reticulum stress in the treatment of ovarian cancer.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is the most common type of cancer among men and the second most frequent cause of cancer-related mortality around the world. The progression of advanced prostate cancer to castration-resistant prostate cancer (CRPC) plays a major role in disease-associated morbidity and mortality, posing a significant therapeutic challenge. Resistance has been associated with the activation of androgen receptors
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.